Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Yoshimoto, Yuya ^a   Suzuki, Yoshiyuki ^a   Mimura, Kousaku ^b,d   Ando, Ken ^a   Oike, Takahiro ^a   Sato, Hiro ^a   Okonogi, Noriyuki ^a   Maruyama, Takanori ^d   Izawa, Shinichiro ^d   Noda, Shin Ei ^a   Fujii, Hideki ^d   Kono, Koji ^b,c,d   Nakano, Takashi ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FR4 ANTIBODY; GITR ANTIBODY; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOMODULATING AGENT; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; LEWIS CARCINOMA; LYMPHOMA CELL; MOUSE; NONHUMAN; PROTEIN SECRETION; SURVIVAL TIME; T CELL DEPLETION; THERAPY EFFECT; TREATMENT DURATION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME; X IRRADIATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; IMMUNOLOGY; LYMPHOMA; PROCEDURES; RADIATION DOSE; RADIOTHERAPY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, LEWIS LUNG; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN G; LYMPHOMA; MICE; MICE, INBRED C57BL; RADIOTHERAPY; RADIOTHERAPY DOSAGE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84899865378     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092572     Document Type: Article

References (18)

1. Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, et al. (2012) Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 72: 3967-3976.
2. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, et al. (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366: 925-931.
3. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, et al. (2004) Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58: 862-870. (Pubitemid 38221143)
4. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, et al. (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059. (Pubitemid 47517504)
5. von Boehmer H and Daniel C (2013) Therapeutic opportunities for manipulating Treg cells in autoimmunity and cancer. Nat Rev Drug Discovery, 12, 51-63.
6. Verginis P, McLaughlin KA, Wucherpfennig KW, von Boehmer H and Apostolou I (2008) Induction of antigen-specific regulatory T cells in wild-type mice: visualization and targets of suppression. Proc Natl Acad Sci USA, 105, 3479-3484. (Pubitemid 351723578)
7. Mempel TR, Pittet MJ, Khazaie K, Weninger W, Weissleder R, et,al. (2006) Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity, 25, 129-141. (Pubitemid 44066829)
8. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, et al. (2009) Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114: 589-595.
9. Takeshima T, Chamoto K, Wakita D, Ohkuri T, Togashi Y, et al. (2010) Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res 70: 2697-2706.
10. Pardoll DM. (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264.
11. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP (2009) Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206: 1717-1725.
12. Grosso JF, Jure-Kunkel MN. (2013) CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer immunity 13: 5-18.
13. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, et al. (2005) Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11: 728-734. (Pubitemid 40116901)
14. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, et al. (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15: 5379-5388.
15. Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T, et al. (2007) Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 27: 145-159. (Pubitemid 47089022)
16. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, et al. (2005) Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 202: 885-891. (Pubitemid 41396888)
17. Schaer DA, Murphy JT, Wolchok JD (2012) Modulation of GITR for cancer immunotherapy. Curr Opin Immunol 24: 217-224.
18. Takeda K, Kojima Y, Uno T, Hayakawa Y, Teng MWL, et al. (2010) Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. J Immunol 184: 5493-5501.